S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
UK Treasury chief says he'll hike the minimum wage but rules out tax cuts while inflation stays high
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
UK Treasury chief says he'll hike the minimum wage but rules out tax cuts while inflation stays high
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
UK Treasury chief says he'll hike the minimum wage but rules out tax cuts while inflation stays high
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
UK Treasury chief says he'll hike the minimum wage but rules out tax cuts while inflation stays high
NASDAQ:CYCC

Cyclacel Pharmaceuticals (CYCC) Stock Forecast, Price & News

$0.35
+0.01 (+3.11%)
(As of 09/29/2023 08:52 PM ET)
Compare
Today's Range
$0.34
$0.36
50-Day Range
$0.28
$0.72
52-Week Range
$0.28
$1.51
Volume
19,300 shs
Average Volume
74,767 shs
Market Capitalization
$4.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Cyclacel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,155.4% Upside
$8.00 Price Target
Short Interest
Bearish
4.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Cyclacel Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.65) to ($3.04) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars


CYCC stock logo

About Cyclacel Pharmaceuticals (NASDAQ:CYCC) Stock

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

CYCC Price History

CYCC Stock News Headlines

How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Jointown Pharmaceutical Group
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Cyclacel Pharmaceuticals (NASDAQ: CYCC)
Cyclacel Pharmaceuticals's Earnings Outlook
See More Headlines
Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CYCC Company Calendar

Last Earnings
8/09/2023
Today
10/02/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYCC
Employees
2,018
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+2,155.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-21,200,000.00
Pretax Margin
-7,578.55%

Debt

Sales & Book Value

Annual Sales
$373,000.00
Book Value
$1.24 per share

Miscellaneous

Free Float
11,642,000
Market Cap
$4.48 million
Optionable
Not Optionable
Beta
1.13
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Spiro George RombotisMr. Spiro George Rombotis (Age 64)
    Pres, CEO & Exec. Director
    Comp: $763.55k
  • Mr. Paul McBarron (Age 62)
    Exec. VP of Fin., CFO, COO, Sec. & Exec. Director
    Comp: $394.68k
  • Dr. Mark H. Kirschbaum M.D. (Age 62)
    Sr. VP & Chief Medical Officer
    Comp: $523.84k
  • Ms. Gill Christie (Age 66)
    Director of HR













CYCC Stock - Frequently Asked Questions

Should I buy or sell Cyclacel Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYCC shares.
View CYCC analyst ratings
or view top-rated stocks.

What is Cyclacel Pharmaceuticals' stock price forecast for 2023?

2 brokers have issued 1-year target prices for Cyclacel Pharmaceuticals' shares. Their CYCC share price forecasts range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 2,155.4% from the stock's current price.
View analysts price targets for CYCC
or view top-rated stocks among Wall Street analysts.

How have CYCC shares performed in 2023?

Cyclacel Pharmaceuticals' stock was trading at $0.6670 on January 1st, 2023. Since then, CYCC shares have decreased by 46.8% and is now trading at $0.3547.
View the best growth stocks for 2023 here
.

Are investors shorting Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 456,600 shares, an increase of 7.0% from the August 31st total of 426,900 shares. Based on an average daily trading volume, of 93,400 shares, the days-to-cover ratio is presently 4.9 days. Approximately 4.2% of the company's stock are short sold.
View Cyclacel Pharmaceuticals' Short Interest
.

When is Cyclacel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our CYCC earnings forecast
.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its earnings results on Wednesday, August, 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.10. The biotechnology company earned $0.37 million during the quarter.

When did Cyclacel Pharmaceuticals' stock split?

Shares of Cyclacel Pharmaceuticals reverse split on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 14th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?

1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $0.35.

How much money does Cyclacel Pharmaceuticals make?

Cyclacel Pharmaceuticals (NASDAQ:CYCC) has a market capitalization of $4.48 million and generates $373,000.00 in revenue each year. The biotechnology company earns $-21,200,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Cyclacel Pharmaceuticals have?

The company employs 2,018 workers across the globe.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The official website for the company is www.cyclacel.com. The biotechnology company can be reached via phone at (908) 517-7330, via email at ir@cyclacel.com, or via fax at 866-271-3466.

This page (NASDAQ:CYCC) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -